Caladrius Biosciences Profit Margin

Caladrius Biosciences (CLBS) currently reports a profit margin of -14621.0% as of June 2026. That compares with 13.37% in the prior-year period — down 109429.1% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Caladrius Biosciences's profit margin history and peer comparisons.

Caladrius Biosciences's profit margin decreased from 13.37% to -14621.0% — a 109429.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Caladrius Biosciences's profit margin of -14621.0% is lower than the Healthcare sector average of 13.89%. That is roughly 105339.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Caladrius Biosciences's current -14621.0% should be judged against Healthcare norms (sector average: 13.89%) and against CLBS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -14621.0%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Caladrius Biosciences, and consider following CLBS for alerts when major investors trade the stock.